Bexarotene.
D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D000077610:Bexarotene; D004347:Drug Interactions; D006801:Humans; D016410:Lymphoma, T-Cell, Cutaneous / Q000188:drug therapy*; D013764:Tetrahydronaphthalenes / Q000009:adverse effects / Q000627:therapeutic use*
D000970:Antineoplastic Agents; D013764:Tetrahydronaphthalenes; D000077610:Bexarotene